logo-loader

Orthocell study shows Remplir outperforms traditional suture-only nerve repair

Last updated: 12:30 20 Jun 2025 AEST, First published: 11:30 20 Jun 2025 AEST

Orthocell has reported promising interim results from a new study which investigated the role of sutures in nerve repair.

The study showed that its flagship "Remplir" product delivers superior outcomes compared with the traditional suture-only method/ and highlights Remplir’s potential to redefine the nerve repair market.

Orthocell’s CEO and MD, Paul Anderson, said: “These Study results provide key data to support the U.S. product sales roll out and rapid market adoption and will be a cornerstone of our US medical education efforts.”

#Orthocell #Remplir #NerveRepair #RegenerativeMedicine #MedicalInnovation #ClinicalStudy #USHealthcare #PeripheralNerveInjury #BiotechAustralia #MedTech #SuturelessRepair #PaulAnderson

Orthocell CEO on Remplir sales in Thailand as global footprint grows

Orthocell Ltd (ASX:OCC, OTC:ORHHF) managing director and CEO Paul Anderson spoke with Proactive's Stephen Gunnion about the company recording its first Remplir sales in Thailand, expanding the global commercial footprint of its nerve repair product. Anderson said the milestone forms part of...

on 22/9/26